|
Patent landscape, scope, and claims: |
United States Patent 11,819,480: Scope, Claims, and Landscape Analysis
This report analyzes United States Patent 11,819,480, focusing on its scope, key claims, and the surrounding patent landscape. The patent, titled "APPARATUS FOR ADMINISTRATION OF NANOPARTICLES" and issued on November 14, 2023, by Nanosupplies GmbH, describes an apparatus designed for delivering nanoparticles, particularly within a biological context.
What is the Core Technology Protected by Patent 11,819,480?
Patent 11,819,480 protects an apparatus for administering nanoparticles. The apparatus is designed to facilitate the controlled delivery of these particles, which can range in size from 1 nm to 1000 nm. The system includes a reservoir for the nanoparticles, a transport mechanism to move them from the reservoir, and an outlet for their release. A key aspect of the invention is its ability to manage nanoparticle aggregation, a common challenge in such delivery systems. The apparatus can be configured for various administration routes, including injection, inhalation, and topical application.
The system integrates components such as a housing, a fluid source, and at least one nozzle or aperture. The transport mechanism can involve fluid flow, mechanical agitation, or electric fields to ensure the nanoparticles remain dispersed and are efficiently delivered. The patent specifically addresses the prevention of clogging and the maintenance of nanoparticle integrity during the administration process.
What are the Key Claims of Patent 11,819,480?
The patent's claims define the legal boundaries of the protected invention. The independent claims are crucial for understanding the breadth of protection.
Claim 1: This claim defines the fundamental apparatus. It includes:
- A housing.
- A reservoir for storing nanoparticles in a carrier liquid.
- A carrier liquid source.
- A transport mechanism configured to transport nanoparticles from the reservoir.
- An outlet configured to release the nanoparticles.
- A control unit operatively connected to the transport mechanism and the carrier liquid source.
The control unit is described as being configured to control the transport mechanism and the carrier liquid source to administer a predetermined dose of nanoparticles. Crucially, the transport mechanism is designed to prevent aggregation of the nanoparticles. The apparatus can further include an aggregation prevention system, such as a mixing element or a flow modifier.
Claim 12: This claim recasts the invention as a method for administering nanoparticles. The method comprises:
- Storing nanoparticles in a carrier liquid within a reservoir.
- Transporting nanoparticles from the reservoir using a transport mechanism.
- Releasing the nanoparticles through an outlet.
- Controlling the transport mechanism and carrier liquid flow to administer a predetermined dose.
- Preventing nanoparticle aggregation during transport.
Dependent Claims: Numerous dependent claims further refine the scope, detailing specific configurations and functionalities. For example, dependent claims specify:
- The size range of the nanoparticles (1 nm to 1000 nm).
- The type of carrier liquid (aqueous or non-aqueous).
- The nature of the transport mechanism (e.g., pump, peristaltic system, ultrasonic transducer).
- Specific methods for aggregation prevention (e.g., shear forces, dilution, introduction of stabilizing agents).
- Configurations for different administration routes (e.g., needle-based, nebulizer, transdermal patch).
- Integration with sensors for real-time monitoring of nanoparticle concentration and delivery parameters.
How is the Apparatus Configured for Different Administration Routes?
The patent outlines distinct configurations for various administration routes, demonstrating the versatility of the core apparatus.
-
Injectable Administration: For subcutaneous, intramuscular, or intravenous delivery, the apparatus typically includes a fine-gauge needle or cannula connected to the outlet. The transport mechanism is optimized for precise, controlled volumetric delivery. The aggregation prevention system is vital here to avoid embolism or blockages. The control unit manages flow rate and volume to ensure accurate dosing and minimize tissue damage.
-
Inhalation Administration: For pulmonary delivery, the apparatus is adapted into a nebulizer or inhaler device. The outlet is designed to generate an aerosol of nanoparticles with a specific particle size distribution suitable for deep lung penetration. This may involve ultrasonic vibration, jet nebulization, or other aerosol generation technologies. The carrier liquid is selected for safe inhalation, and the transport mechanism ensures consistent aerosol production.
-
Topical and Transdermal Administration: For skin application, the apparatus can be integrated into patches, creams, or gels. The outlet may be a porous membrane or a dispensing nozzle. The transport mechanism controls the rate of release onto the skin surface or for penetration through the stratum corneum. Nanoparticle formulations are optimized for skin compatibility and controlled release.
The common thread across these configurations is the underlying principle of controlled nanoparticle transport and aggregation prevention managed by the control unit.
What are the Key Challenges Addressed by the Invention?
The invention in Patent 11,819,480 directly addresses several critical challenges in nanoparticle administration:
-
Nanoparticle Aggregation: Nanoparticles, due to their high surface area to volume ratio, tend to aggregate in liquid suspensions. This aggregation can lead to uneven dosing, blockage of delivery devices, and reduced therapeutic efficacy. The patent's core innovation lies in its integrated transport and aggregation prevention mechanisms.
-
Precise Dosing: Delivering a consistent and accurate dose of nanoparticles is essential for therapeutic outcomes and patient safety. Variations in dose can lead to under-treatment or toxicity. The control unit and regulated transport mechanism are designed to ensure precise volumetric or mass-based delivery.
-
Device Clogging: Aggregated nanoparticles or debris can clog narrow channels or nozzles in delivery devices, rendering them inoperable. The aggregation prevention system and the design of the transport pathway aim to mitigate this.
-
Nanoparticle Integrity: The administration process itself can potentially damage fragile nanoparticles. The apparatus is designed to minimize shear forces and other disruptive physical stresses during transport and delivery.
-
Versatility and Compatibility: The need for different administration routes for various therapeutic applications requires a flexible system. The patent demonstrates how the core technology can be adapted for injectables, inhalables, and topical applications.
Who are the Key Players in the Nanoparticle Administration Technology Landscape?
The field of nanoparticle drug delivery is dynamic, with significant activity from pharmaceutical companies, biotechnology firms, and academic institutions. Analyzing the patent landscape surrounding Patent 11,819,480 provides context.
Major Patent Holders and Applicants in Nanoparticle Delivery Systems:
-
Pharmaceutical Giants: Companies like Pfizer Inc., Novartis AG, Johnson & Johnson, and Merck & Co. hold numerous patents related to drug formulations and delivery systems, including those involving nanoparticles for various therapeutic areas (e.g., oncology, infectious diseases). Their patents often focus on specific nanoparticle compositions, targeting ligands, and therapeutic payloads.
-
Biotechnology Companies: Firms specializing in drug delivery technologies, such as Arbutus Biopharma Corporation, Moderna, Inc. (particularly for mRNA delivery), and BioNTech SE, are active in patenting novel delivery vehicles and methods. These often involve lipid nanoparticles (LNPs) or polymer-based nanoparticles.
-
Device Manufacturers: Companies focused on medical devices for drug administration, such as Becton, Dickinson and Company, Medtronic plc, and Abbott Laboratories, may patent the mechanical and electronic aspects of drug delivery devices, including those designed to handle complex formulations like nanoparticles.
-
Academic Institutions: Leading universities globally (e.g., MIT, Stanford, Harvard, ETH Zurich) frequently patent foundational technologies in nanotechnology and drug delivery, which are then licensed to commercial entities. Nanosupplies GmbH, the assignee of Patent 11,819,480, appears to be a commercial entity focused on these specific types of advanced materials and delivery solutions.
Key Technology Areas within the Landscape:
-
Lipid Nanoparticles (LNPs): Dominant for nucleic acid delivery (mRNA, siRNA). Patents cover LNP composition, manufacturing processes, and in vivo performance.
-
Polymeric Nanoparticles: Used for controlled release of small molecules and biologics. Patents focus on polymer types, fabrication methods, and drug loading.
-
Dendrimers and Micelles: Explored for their unique structures and encapsulation capabilities.
-
Inorganic Nanoparticles: Such as gold nanoparticles and quantum dots, used for imaging and therapeutic applications.
-
Smart Delivery Systems: Nanoparticles that respond to stimuli (e.g., pH, temperature, enzymes) for targeted release.
Patent 11,819,480 occupies a niche within this landscape by focusing on the apparatus for administering any type of nanoparticle, emphasizing the engineering challenges of delivery rather than the specific nanoparticle formulation itself. This suggests a focus on the interface between the drug product and the patient delivery mechanism. Its breadth lies in its potential applicability across various nanoparticle types and delivery routes.
How Does Patent 11,819,480 Compare to Existing Nanoparticle Delivery Technologies?
The novelty and distinctiveness of Patent 11,819,480 lie in its comprehensive approach to the delivery apparatus, specifically addressing aggregation and precise dosing across multiple administration routes.
-
Focus on Apparatus vs. Formulation: Many existing patents focus on the nanoparticle formulation itself – its composition, surface chemistry, or therapeutic payload. Patent 11,819,480 shifts the focus to the engineering of the device that administers these particles. This is a critical distinction, as effective delivery is as vital as the drug itself.
-
Integrated Aggregation Prevention: While other systems might address aggregation within the formulation stage, this patent claims an apparatus with integrated mechanisms to prevent aggregation during the transport and administration process. This is particularly relevant for devices that store the formulation for extended periods or require complex fluidic paths.
-
Route Agnosticism (with adaptation): The patent is not limited to a single administration route. By detailing configurations for injection, inhalation, and topical application, it aims for a platform technology. Many other delivery device patents are more specific to a single route (e.g., an insulin pen, a specific nebulizer).
-
Control and Precision: The emphasis on a "control unit" for managing transport and carrier liquid flow to achieve a "predetermined dose" highlights a focus on sophisticated engineering for precision, which is often a challenge with complex nanomaterials.
Table 1: Comparison of Nanoparticle Delivery Patent Focus Areas
| Patent Focus Area |
Typical Patent Scope |
Example Technologies |
Relevance to 11,819,480 |
| Nanoparticle Formulation |
Chemical composition, surface modifications, encapsulation methods, drug loading efficiency, targeting moieties. |
Lipids, polymers, inorganic materials, specific drug conjugates. |
Provides the material that 11,819,480's apparatus is designed to deliver. This patent complements formulation patents by enabling effective delivery of those formulations. |
| Nanoparticle Manufacturing |
Methods for scalable, reproducible production of nanoparticles with desired size and properties. |
Emulsification, nanoprecipitation, microfluidics. |
Ensures a consistent supply of nanoparticles suitable for use with the apparatus. The apparatus's performance can be influenced by the quality of manufactured nanoparticles. |
| Specific Administration Devices |
Devices tailored for a single route of administration (e.g., inhalers, injectors). |
Metered-dose inhalers, auto-injectors, transdermal patches. |
11,819,480 claims a broader apparatus that can be adapted for multiple routes, suggesting a platform approach rather than a single-use device. |
| Apparatus for Nanoparticle Admin. |
Engineering of devices to handle nanoparticle transport, prevent aggregation, and ensure precise dosing across routes. |
Reservoirs, transport mechanisms, control units, aggregation prevention systems. |
This is the core focus of 11,819,480. Its novelty is in the integrated engineering solutions for common delivery challenges, independent of the specific nanoparticle type. |
The patent's strength lies in its focus on the practical, engineering challenges of getting nanoparticles into the body effectively and safely. This makes it relevant to a broad range of companies developing nanoparticle-based therapeutics.
What are the Potential Commercial Implications?
The commercial implications of Patent 11,819,480 are significant for companies involved in nanoparticle drug development and delivery devices.
-
Licensing Opportunities: Companies developing novel nanoparticle therapeutics could license this patent to integrate with their delivery device strategies, potentially accelerating their product development timelines and reducing R&D risk associated with delivery challenges.
-
Competitive Barrier: For companies seeking to develop new nanoparticle delivery devices, this patent represents a potential barrier to entry if their technology infringes upon its claims, particularly regarding aggregation prevention and controlled dose delivery.
-
Platform Technology: The patent's adaptability across different administration routes positions it as a potential platform technology. Companies could leverage this apparatus for multiple drug products or therapeutic areas, creating a standardized delivery solution.
-
Enhanced Therapeutic Efficacy: By ensuring more consistent and accurate delivery of nanoparticles, the apparatus protected by this patent could lead to improved therapeutic outcomes, increased drug efficacy, and potentially reduced side effects, making it attractive to pharmaceutical developers.
-
Market Differentiation: For device manufacturers, adopting or licensing this technology could provide a competitive edge by offering a solution that addresses known limitations in nanoparticle delivery.
The patent's broad claims, covering the fundamental apparatus for administering nanoparticles, suggest a wide scope of potential application and commercial interest.
Key Takeaways
- Patent 11,819,480 protects a novel apparatus for administering nanoparticles, addressing critical challenges of aggregation and precise dosing.
- The invention comprises a housing, reservoir, transport mechanism, outlet, and control unit, designed to manage nanoparticle dispersion during delivery.
- Key claims focus on the integrated prevention of nanoparticle aggregation and the controlled release of predetermined doses.
- The apparatus is configurable for multiple administration routes, including injection, inhalation, and topical/transdermal delivery, offering platform potential.
- This patent complements nanoparticle formulation patents by focusing on the critical engineering aspects of the delivery device.
- Commercial implications include significant licensing opportunities, potential competitive barriers, and the possibility of establishing a platform technology for nanoparticle therapeutics.
Frequently Asked Questions
-
Does Patent 11,819,480 cover specific nanoparticle formulations?
No, the patent primarily covers the apparatus and method for administering nanoparticles, not the specific chemical composition or type of nanoparticle formulation itself.
-
What is the primary technical challenge this patent aims to solve?
The patent's primary technical challenge is to prevent nanoparticle aggregation during transport and administration, ensuring consistent dosing and device functionality.
-
Can this apparatus be used for both small molecule drugs and biologics delivered via nanoparticles?
Yes, the apparatus is described as being for the administration of "nanoparticles," which can encapsulate various types of therapeutic agents, including small molecules and biologics.
-
How does the control unit function in this apparatus?
The control unit is configured to regulate the transport mechanism and the carrier liquid source to ensure a precise, predetermined dose of nanoparticles is administered, and to manage the aggregation prevention systems.
-
What administration routes are explicitly mentioned or implied by the patent?
The patent explicitly mentions configurations for injection, inhalation, and topical/transdermal administration.
Citations
[1] Nanosupplies GmbH. (2023). Apparatus for administration of nanoparticles (U.S. Patent No. 11,819,480). Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
